Skip to main content
Erschienen in: Forensic Toxicology 1/2020

26.08.2019 | Original Article

In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: phase I and II metabolism, plasma protein binding, and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry

verfasst von: Lilian H. J. Richter, Julia Menges, Lea Wagmann, Simon D. Brandt, Alexander Stratford, Folker Westphal, Veit Flockerzi, Markus R. Meyer

Erschienen in: Forensic Toxicology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Toxicokinetic studies are essential in clinical and forensic toxicology to understand drug–drug interactions, influence of individual polymorphisms, and elimination routes, as well as to evaluate targets for toxicological screening procedures. N-(2-Methoxybenzyl)-substituted phenethylamines (NBOMe analogues) intake has been associated with severe adverse reactions including deaths. 1-(1-Benzofuran-5-yl)-N-[(2-methoxyphenyl)methyl]propan-2-amine (5-APB-NBOMe), 2-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b′]difuran-4-yl)-N-[(5-chloro-2-ethoxyphenyl)methyl]ethan-1-amine (2C-B-FLY-NB2EtO5Cl), and 2-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b′]difuran-4-yl)-N-[(2-methoxyphenyl)methyl]ethan-1-amine (2C-B-FLY-NBOMe) are three emerging NBOMe analogues, which have encountered on the drugs of abuse market. So far, their toxicokinetic data are completely unexplored.

Methods

The study included mass spectrometry-based identification of phase I and II metabolites following exposure to the terminally differentiated human hepatocellular carcinoma cells (HepaRG). The determination of enzymes involved in the major phase I/II metabolic steps and determination of plasma protein binding (PPB) were done. Finally, the evaluation of the toxicological detectability by different hyphenated mass spectrometry techniques in standard urine screening approaches (SUSAs) was investigated.

Results

The compounds were extensively metabolized in HepaRG cells mainly via O-dealkylation, hydroxylation, glucuronidation, and combinations thereof. CYP1A2, 2D6, 2C8, 2C19, and 3A4, were involved in the initial reactions of all investigated compounds. Glucuronidation of the phase I metabolites—when observed—was mainly catalyzed by UGT1A9. The PPB of all compounds was determined to be > 85%. Only the high-resolution mass spectrometry-based SUSA allowed detection of all compounds in rat urine, but only via metabolites.

Conclusions

The toxicokinetic data provided by this study will help forensic and clinical toxicologists to reliably identify these substances in case of abuse and/or intoxication and will allow them a thorough risk assessment.
Literatur
1.
Zurück zum Zitat Evans-Brown M, Sedefov R (2018) Responding to new psychoactive substances in the European Union: early warning, risk assessment, and control measures. Handb Exp Pharmacol 252:3–49CrossRef Evans-Brown M, Sedefov R (2018) Responding to new psychoactive substances in the European Union: early warning, risk assessment, and control measures. Handb Exp Pharmacol 252:3–49CrossRef
2.
Zurück zum Zitat Tettey JNA, Crean C, Ifeagwu SC, Raithelhuber M (2018) Emergence, diversity, and control of new psychoactive substances: a global perspective. Handb Exp Pharmacol 252:51–67CrossRef Tettey JNA, Crean C, Ifeagwu SC, Raithelhuber M (2018) Emergence, diversity, and control of new psychoactive substances: a global perspective. Handb Exp Pharmacol 252:51–67CrossRef
3.
Zurück zum Zitat Halberstadt AL (2017) Pharmacology and toxicology of N-benzylphenethylamine (“NBOMe”) hallucinogens. Curr Topic Behav Neurosci 32:283–311CrossRef Halberstadt AL (2017) Pharmacology and toxicology of N-benzylphenethylamine (“NBOMe”) hallucinogens. Curr Topic Behav Neurosci 32:283–311CrossRef
4.
Zurück zum Zitat Caspar AT, Brandt SD, Stoever AE, Meyer MR, Maurer HH (2017) Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MS(n), and LC-HR-MS/MS approaches. J Pharm Biomed Anal 134:158–169CrossRef Caspar AT, Brandt SD, Stoever AE, Meyer MR, Maurer HH (2017) Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MS(n), and LC-HR-MS/MS approaches. J Pharm Biomed Anal 134:158–169CrossRef
5.
Zurück zum Zitat Caspar AT, Helfer AG, Michely JA, Auwarter V, Brandt SD, Meyer MR et al (2015) Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS. Anal Bioanal Chem 407:6697–6719CrossRef Caspar AT, Helfer AG, Michely JA, Auwarter V, Brandt SD, Meyer MR et al (2015) Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS. Anal Bioanal Chem 407:6697–6719CrossRef
6.
Zurück zum Zitat Poklis JL, Dempsey SK, Liu K, Ritter JK, Wolf C, Zhang S et al (2015) Identification of metabolite biomarkers of the designer hallucinogen 25I-NBOMe in mouse hepatic microsomal preparations and human urine samples associated with clinical intoxication. J Anal Toxicol 39:607–616CrossRef Poklis JL, Dempsey SK, Liu K, Ritter JK, Wolf C, Zhang S et al (2015) Identification of metabolite biomarkers of the designer hallucinogen 25I-NBOMe in mouse hepatic microsomal preparations and human urine samples associated with clinical intoxication. J Anal Toxicol 39:607–616CrossRef
7.
Zurück zum Zitat Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6:764–769CrossRef Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6:764–769CrossRef
8.
Zurück zum Zitat Poklis JL, Raso SA, Alford KN, Poklis A, Peace MR (2015) Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and other dimethoxyphenyl-N-[(2-methoxyphenyl)methyl]ethanamine derivatives on blotter paper. J Anal Toxicol 39:617–623CrossRef Poklis JL, Raso SA, Alford KN, Poklis A, Peace MR (2015) Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and other dimethoxyphenyl-N-[(2-methoxyphenyl)methyl]ethanamine derivatives on blotter paper. J Anal Toxicol 39:617–623CrossRef
9.
Zurück zum Zitat Richter LHJ, Flockerzi V, Maurer HH, Meyer MR (2017) Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. J Pharm Biomed Anal 143:32–42CrossRef Richter LHJ, Flockerzi V, Maurer HH, Meyer MR (2017) Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. J Pharm Biomed Anal 143:32–42CrossRef
10.
Zurück zum Zitat Caspar AT, Meyer MR, Maurer HH (2018) Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett 285:1–8CrossRef Caspar AT, Meyer MR, Maurer HH (2018) Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett 285:1–8CrossRef
11.
Zurück zum Zitat Ameline A, Farrugia A, Raul JS, Kintz P (2017) Retrospective demonstration of 25I-NBOMe acute poisoning using hair analysis. Curr Pharm Biotechnol 18:786–790CrossRef Ameline A, Farrugia A, Raul JS, Kintz P (2017) Retrospective demonstration of 25I-NBOMe acute poisoning using hair analysis. Curr Pharm Biotechnol 18:786–790CrossRef
12.
Zurück zum Zitat Rose SR, Poklis JL, Poklis A (2013) A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) 51:174–177CrossRef Rose SR, Poklis JL, Poklis A (2013) A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) 51:174–177CrossRef
13.
Zurück zum Zitat Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27–34CrossRef Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27–34CrossRef
14.
Zurück zum Zitat Heim R (2003) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. Freie Universität Berlin, Germany.Ph.D. dissertation Heim R (2003) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. Freie Universität Berlin, Germany.Ph.D. dissertation
15.
Zurück zum Zitat Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE (1996) Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem 39:2953–2961CrossRef Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE (1996) Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem 39:2953–2961CrossRef
16.
Zurück zum Zitat Halberstadt AL, Chatha M, Stratford A, Grill M, Brandt SD (2019) Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran (“FLY”) and benzodifuran (“DragonFLY”) analogs. Neuropharmacology 144:368–376CrossRef Halberstadt AL, Chatha M, Stratford A, Grill M, Brandt SD (2019) Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran (“FLY”) and benzodifuran (“DragonFLY”) analogs. Neuropharmacology 144:368–376CrossRef
18.
Zurück zum Zitat Noble C, Holm NB, Mardal M, Linnet K (2018) Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A. Toxicol Lett 295:397–407CrossRef Noble C, Holm NB, Mardal M, Linnet K (2018) Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A. Toxicol Lett 295:397–407CrossRef
19.
Zurück zum Zitat Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M et al (2011) Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. Eur J Nucl Med Mol Imaging 38:681–693CrossRef Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M et al (2011) Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. Eur J Nucl Med Mol Imaging 38:681–693CrossRef
21.
Zurück zum Zitat Westphal F, Girreser U, Waldmuller D (2016) Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs. Drug Test Anal 8:910–919CrossRef Westphal F, Girreser U, Waldmuller D (2016) Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs. Drug Test Anal 8:910–919CrossRef
22.
Zurück zum Zitat Liu C, Jia W, Qian Z, Li T, Hua Z (2017) Identification of five substituted phenethylamine derivatives 5-MAPDB, 5-AEDB, MDMA methylene homolog, 6-Br-MDMA, and 5-APB-NBOMe. Drug Test Anal 9:199–207CrossRef Liu C, Jia W, Qian Z, Li T, Hua Z (2017) Identification of five substituted phenethylamine derivatives 5-MAPDB, 5-AEDB, MDMA methylene homolog, 6-Br-MDMA, and 5-APB-NBOMe. Drug Test Anal 9:199–207CrossRef
23.
Zurück zum Zitat Caspar AT, Westphal F, Meyer MR, Maurer HH (2018) LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques. Anal Bioanal Chem 410:897–912CrossRef Caspar AT, Westphal F, Meyer MR, Maurer HH (2018) LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques. Anal Bioanal Chem 410:897–912CrossRef
24.
Zurück zum Zitat Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (2019) Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Drug Test Anal 11:318–324CrossRef Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (2019) Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Drug Test Anal 11:318–324CrossRef
26.
Zurück zum Zitat Wagmann L, Meyer MR, Maurer HH (2016) What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett 258:55–70CrossRef Wagmann L, Meyer MR, Maurer HH (2016) What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett 258:55–70CrossRef
27.
Zurück zum Zitat Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR (2016) Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212–2 studied using in vitro tools and LC-HR-MS/MS. Drug Test Anal 8:1039–1048CrossRef Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR (2016) Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212–2 studied using in vitro tools and LC-HR-MS/MS. Drug Test Anal 8:1039–1048CrossRef
28.
Zurück zum Zitat Fung EN, Chen YH, Lau YY (2003) Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 795:187–194CrossRef Fung EN, Chen YH, Lau YY (2003) Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 795:187–194CrossRef
29.
Zurück zum Zitat Wagmann L, Brandt SD, Kavanagh PV, Maurer HH, Meyer MR (2017) In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks. Toxicol Lett 272:84–93CrossRef Wagmann L, Brandt SD, Kavanagh PV, Maurer HH, Meyer MR (2017) In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks. Toxicol Lett 272:84–93CrossRef
30.
Zurück zum Zitat Helfer AG, Turcant A, Boels D, Ferec S, Lelievre B, Welter J et al (2015) Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. Drug Test Anal 7:368–375CrossRef Helfer AG, Turcant A, Boels D, Ferec S, Lelievre B, Welter J et al (2015) Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. Drug Test Anal 7:368–375CrossRef
31.
Zurück zum Zitat Welter J, Kavanagh P, Meyer MR, Maurer HH (2015) Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques. Anal Bioanal Chem 407:1371–1388CrossRef Welter J, Kavanagh P, Meyer MR, Maurer HH (2015) Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques. Anal Bioanal Chem 407:1371–1388CrossRef
32.
Zurück zum Zitat Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907–921CrossRef Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907–921CrossRef
33.
Zurück zum Zitat Maurer HH, Pfleger K, Weber AA (2016) Mass spectral data of drugs, poisons, pesticides, pollutants and their metabolites. Wiley-VCH, Weinheim Maurer HH, Pfleger K, Weber AA (2016) Mass spectral data of drugs, poisons, pesticides, pollutants and their metabolites. Wiley-VCH, Weinheim
34.
Zurück zum Zitat Meyer MR, Lindauer C, Welter J, Maurer HH (2014) Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography-linear ion-trap (high-resolution) mass spectrometry. Anal Bioanal Chem 406:1845–1854CrossRef Meyer MR, Lindauer C, Welter J, Maurer HH (2014) Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography-linear ion-trap (high-resolution) mass spectrometry. Anal Bioanal Chem 406:1845–1854CrossRef
35.
Zurück zum Zitat Maurer HH, Wissenbach DK, Weber AA (2018) Maurer/Wissenbach/Weber MWW LC-MSn library of drugs, poisons, and their metabolites, 2nd edn. Wiley-VCH, Weinheim Maurer HH, Wissenbach DK, Weber AA (2018) Maurer/Wissenbach/Weber MWW LC-MSn library of drugs, poisons, and their metabolites, 2nd edn. Wiley-VCH, Weinheim
36.
Zurück zum Zitat Maurer HH, Meyer MR, Helfer AG, Weber AA (2018) Maurer/Meyer/Helfer/Weber MMHW LC-HR-MS/MS library of drugs, poisons, and their metabolites. Wiley-VCH, Weinheim Maurer HH, Meyer MR, Helfer AG, Weber AA (2018) Maurer/Meyer/Helfer/Weber MMHW LC-HR-MS/MS library of drugs, poisons, and their metabolites. Wiley-VCH, Weinheim
37.
Zurück zum Zitat Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR (2002) Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 64:1355–1374CrossRef Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR (2002) Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 64:1355–1374CrossRef
38.
Zurück zum Zitat Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR (2004) Predicting plasma protein binding of drugs—revisited. Curr Opin Drug Discov Devel 7:507–512PubMed Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR (2004) Predicting plasma protein binding of drugs—revisited. Curr Opin Drug Discov Devel 7:507–512PubMed
Metadaten
Titel
In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: phase I and II metabolism, plasma protein binding, and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry
verfasst von
Lilian H. J. Richter
Julia Menges
Lea Wagmann
Simon D. Brandt
Alexander Stratford
Folker Westphal
Veit Flockerzi
Markus R. Meyer
Publikationsdatum
26.08.2019
Verlag
Springer Singapore
Erschienen in
Forensic Toxicology / Ausgabe 1/2020
Print ISSN: 1860-8965
Elektronische ISSN: 1860-8973
DOI
https://doi.org/10.1007/s11419-019-00498-7

Weitere Artikel der Ausgabe 1/2020

Forensic Toxicology 1/2020 Zur Ausgabe

Neu im Fachgebiet Rechtsmedizin

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Molekularpathologische Untersuchungen im Wandel der Zeit

11.04.2024 | Pathologie | Schwerpunkt: Next Generation Pathology

Vergleichende Pathologie in der onkologischen Forschung

Open Access 08.04.2024 | GIST | CME

Gastrointestinale Stromatumoren

Wo stehen wir?

03.04.2024 | Zielgerichtete Therapie | Schwerpunkt: Next Generation Pathology

Personalisierte Medizin in der Onkologie